# A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer

> **NCT04306926** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 59 (estimated)

## Conditions studied

- Advanced Oligometastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TQB2450
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04306926
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-05-30
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04306926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04306926, "A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04306926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*